FDA approves Samsung Bioepis’ Opuviz

2024. 5. 22. 10:36
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Courtesy of Samsung Bioepis]
The U.S. Food and Drug Administration (FDA) has approved Samsung Bioepis’ Opuviz, a biosimilar to blockbuster ophthalmic drug Eylea, for the treatment of various eye diseases. This is first time an Eylea biosimilar has received FDA approval and the authority also approved Yesafili, a biosimilar developed by India’s Biocon Biologics, alongside Opuviz.

The approval, which was announced on Monday (local time), grants interchangeability status to both Opuviz and Yesafili, allowing pharmacies to substitute these biosimilars for Eylea without a physician’s approval. This designation is expected to reduce patient wait times, address drug shortages, and streamline access to biologic drugs.

Opuviz and Yesafili are vascular endothelial growth factor (VEGF) inhibitors, administered via intravitreal injection to treat conditions such as neovascular age-related macular degeneration (AMD), macular edema, and diabetic retinopathy. These conditions, if untreated, can lead to significant vision loss or blindness.

Eylea, originally developed by Regeneron and Bayer AG, recorded $9.21 billion in global sales in 2024, over half of which came from the U.S. market. Eylea works by inhibiting abnormal blood vessel growth and leakage under the retina, which can cause severe pain and vision impairment.

The global macular degeneration treatment market is expected to surge from $7.4 billion in 2021 to $27.5 billion by 2031. The FDA has approved 52 biosimilars to date, according to the Korea Biotechnology Industry Organization. Korean companies have received approval for 11 products, including six from Samsung Bioepis and five from Celltrion Inc.

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?